Please Read Our Disclaimer
Location: Oakville, ON
Sector: Health .
LyfeUp is a personalized health concierge, powered by Artificial Intelligence (AI), built on Blockchain technology to streamline health information including diagnostic test results.
It manages access and storage of the member’s health-related information, understands the member’s current health status, predicts potential health risks, and adjusts their lifestyle for optimum wellness.
LyfeUp offers you a highly secure and convenient, personalized health concierge. It uses Artificial Intelligence to understand your current health status and adjust your lifestyle for optimum wellness. LyfeUp’s Concierge helps you follow your custom lifestyle plan, designed and monitored by our experts, all through a text, voice and video enabled intelligent and automated chat interface, to achieve your goals, 24/7. You can request on-demand video calls with our network of health practitioners, or even order our optional at-home lab kits, diagnosing your body’s Genetics, Hormones, Micronutrients and much more.
LyfeUp is backed by a partner-owned clinic in Ontario (Canada), giving it the ability to offer its international services thru partner health practitioners.
The Chatbot (Concierge), thru its interactive on-boarding process, does an initial assessment for you, to understand your current lifestyle.
Then you will receive a Biometrics Package, which includes a digital scale and activity tracker pre-connected to the subscriber’s profile, allowing them to automatically log their progress without manual entry.
The concierge will also recommend optional at-home diagnostic lab kits for a more detailed holistic view of your body. If lab kits were ordered, follow the instructions to take a sample (saliva, dry blood, dry urine) in the comfort of your home and return it by mail to our certified partner labs for analysis. Subscribers receive special discount on the kits, although you can request them without being a LyfeUp Concierge member at a premium.
Finally, our experts will setup a lifestyle plan for you on the system, and if requested, a one-on-one consultation is available.
The Chatbot (Concierge) will then work with you to follow your lifestyle plan, 24/7, embedding those test results to personalize the advice. Lifestyle advice includes meal planning (food to eat, and if needed cooking recipes), exercises and other helpful recommendations.
Our services are split into Addons (which we provide directly), and Partners services provided by 3rd parties.
The addons include: Intervention where our specialists (physicians, dietitians and others) can provide one-on-one consultations, on demand thru video calls. This service allows our network of participating health practitioners to grow their patients (LyfeUp becomes a patient acquisition channel), while the Concierge takes care of routine followups on their designed lifestyle plans, to make their services much more effective.
We also have a special Diabetes program for those diagnosed with Type II Diabetes as they require specialized care.
And finally, through partnerships with world renowned supplements manufacturers, our system would recommend customized nutraceutical formulas to complement and improve our subscribers’ wellness, which we will ship to their door.
For 3rd party partners’ services, this includes: Surgery (where we refer patients in need of Bariatric or Balloon (Endoscopy) surgeries to our partner surgeons and hospitals in various jurisdictions), programs to deliver meals based on their diet, and Personal Trainers providing discounts for our subscribers.
LyfeUp’s founding team brings diverse skills including: engineering, medical, franchising and financing. They have prior founded and scaled successful ventures into IPOs (NASDAQ). Collectively, the founders and their leading ventures have been featured by various leading media outlets and publications, including: Harvard Business Review, MIT Enterprise Forum, The New York Times, and others.
Hadi Aladdin,Co-founder & CEO
Hadi Aladdin is a serial entrepreneur, engineer, and published author. Being a coder since the age of 11, he has founded and grew successful technology ventures with global reach, including: CoursePeer Inc., ArabCode.org, Kula Technologies Inc., Angstron Technologies Inc. and others, spanning the fields of education technology, food ordering technology, software development consulting and Hyperloop (transportation).
The University of Toronto has recognized Hadi among its top researchers in its Annual Research Report. Hadi has played a vital role in establishing the startup incubation system at the University of Toronto, and he acts as an active founding mentor and judge at the “Entrepreneurship Hatchery” – the formal incubator of the Faculty of Applied Science and Engineering at the University of Toronto.
Hadi’s work has been featured at various reputable publications, including the Harvard Business Review, Deloitte reports, and Dubai School of Government’s Social Media report, and his ventures have been endorsed by government and business leaders such as Justin Trudeau (Canada’s Prime Minister), Omar Hamoui (Investment Partner at Sequoia Capital; Former President, Mobile Ads at Google Inc.; Founder of AdMob), Fadi Ghandour (Founder of ARAMEX and Executive Chairman of Wamda Capital), Ahmad Al Shugairi (activist and media figure in the Middle East), Ilse Treurnicht (CEO of MaRS Discovery District), and Majed Al Suwaidi (Managing Director of Dubai Internet City and Dubai Outsource Zone).
Hadi has been invited as a speaker at various international conferences including the MIT Enterprise Forum, The Annual Conference of the Higher Education Quality Council of Ontario and the IEEE Young Professionals. He is a frequent judge and mentor at various regional and international incubators and competitions including: Startup Weekend, RIC Centre, ICUBE UTM, Humber College, in5 (Dubai Internet City incubator), TURN8, Smart City App Hack and “The Hatchery“.
Education: Bachelor of Applied Science in Computer Engineering, University of Toronto.
Marwan Aladdin, Co-founder & COO
Marwan Aladdin is a serial entrepreneur, engineer, and published author. Being a coder since the age of 11, he has founded and grew successful technology ventures with global reach, including: CoursePeer Inc., ArabCode.org, Kula Technologies Inc., Angstron Technologies Inc. and others, spanning the fields of education technology, food ordering technology, software development consulting and Hyperloop (transportation).
The University of Toronto has recognized Marwan among its top researchers in its Annual Research Report. Marwan has played a vital role in establishing the startup incubation system at the University of Toronto.
Marwan’s work has been featured at various reputable publications, including the Harvard Business Review, Deloitte reports, and Dubai School of Government’s Social Media report, and his ventures have been endorsed by government and business leaders such as Justin Trudeau (Canada’s Prime Minister), Omar Hamoui (Investment Partner at Sequoia Capital; Former President, Mobile Ads at Google Inc.; Founder of AdMob), Fadi Ghandour (Founder of ARAMEX and Executive Chairman of Wamda Capital), Ahmad Al Shugairi (activist and media figure in the Middle East), Ilse Treurnicht (CEO of MaRS Discovery District), and Majed Al Suwaidi (Managing Director of Dubai Internet City and Dubai Outsource Zone).
Marwan has been invited as a speaker at various international conferences including the MIT Enterprise Forum and the Annual Conference of the Higher Education Quality Council of Ontario.
Education: Bachelor of Applied Science in Computer Engineering, University of Toronto.
Ghassan Barazi, Co-founder & President
Ghassan Barazi, a mechanical engineer with a strong entrepreneurial drive, began his career as a business owner in 1989 when he formed CAD Venture, a company specializing in computer aided design for the automotive industry. In 1991, Ghassan tapped into the emerging laser technology industry and co-founded The Laser Eye Institute which, by the end of 1998, evolved into ICON Laser Eye Centres, Inc. ICON quickly became the fastest growing laser vision correction business in the world, trading on NASDAQ. With a global reach extending across North America and Europe and into South America, ICON became the world-leader and international provider of Excimer Laser Vision Correction (LVC), growing to 40 centres world- wide. Ghassan also spent a considerable portion of his career developing highly successful plastic surgery programs for private and public medical facilities in Detroit and Las Vegas prior to 2008 when he became the President & CEO of CI Pharma, a radiopharmaceutical supply company and Care Imaging Cancer Diagnostic Centre, a privatized cancer diagnostic imaging company with locations in both Windsor and the Greater Toronto Area.
After a lengthy career in medical, Ghassan became fascinated with the franchise industry and saw the opportunity in 2011 to purchase the Canadian master licenses for SIGN-A-RAMA, the world’s largest sign franchise and Plan Ahead Events, the world’s largest event management franchise. Both franchises were started by U.S. based United Franchise Group (UFG). Under Ghassan’s leadership, SIGN-A-RAMA Canada expanded into 44 sign centers. After that successful growth, Ghassan has divested his interest in SIGN-A-RAMA Canada and has been focusing his attention on the medical endoscopy/GI clinic, through the acquisition of the Provis-Rudd clinic (founded 1969).
Education: Bachelor of Applied Science in Mechanical Engineering, Ryerson University.
Dr. Cindy Gordon, Advisor, Strategy
Dr. Cindy Gordon is the Founder and CEO of SalesChoice, an AI SaaS Predictive and Prescriptive Guiding Selling Company. She is also an expert in SaaS, AI, business innovation, early-stage software commercialization & sales /marketing practices. She has held senior leadership and partnership roles in global B2B Enterprises, including: Accenture, Xerox, Citicorp and Nortel Networks.
In addition, Cindy has also been a founder, VC, an angel and founder in emerging software companies. She is currently involved in include: Corent Technology, CoursePeer, Kula, LyfeUp, and TouchTown TV. Cindy is also the Founder of Helix Commerce International Inc., a strategy innovation firm which serviced global B2B clients like: CIBC, Davis and Henderson, IBM, ING, LGS Electronics, MTS Allstream, Rogers and TD.
Internationally, she is recognized for her innovation and thought leadership in: SaaS, Collaboration, AI, technology emergence, with over 13 books in the market. She is also a 2012 recipient of the Governor’s General Award for Innovation. She is a 2017 recipient of many awards, including the: STARTUPCANADA National Entrepreneurship Award, CATA & E&Y Sara Kirke Award for Outstanding CEO: Innovation & Community Leadership, and most Creative CEO Award from Insights Success. She is also an Advanced Analytics Expert at the International Institute of Advanced Analytics. She is also currently working on her 14th book on The AI SPLIT: The Perfect World, or The Perfect Storm.
With NFPs, Cindy has a very active community track record including current roles as: AI DIRECTORY, Co-Founder, and Global Chair, CATA (National Media Spokesperson for Innovation, AI, and STEM), Board Director, RSI, and a Mentor for the Enterprise Sales Forum (ESF). Past Roles include: Invest CrowdFund Canada (ICC), National Chair, Women in Technology (CANWIT, CATA), Founding Member, Toronto Maple Leaf Angels. She has also been a Former Board Director for Nightwood Theatre, The Bluma Appel St. LawrenceTheatre. She has also been active in the Canadian Cancer and Prostrate Association, and The United Way.
Education: B.Ed. M.EdAdmin (Information Technology & Decision Support Systems), Doctorate (University of Toronto) (Major: Social Networks and Collaboration Sciences for Innovation Agility).
Ziad Hatahet, Advisor, Technology
Ziad Hatahet is a software engineer with experience in both startups as well as large companies. He has built big data streaming software from the ground up for use in the cybersecurity field of User Entity Behavior Analytics. He has expertise in performance analysis and optimization as well as systems modeling. He comes from a strong Silicon Valley background including such places as Exabeam, Google, and Salesforce. In addition, he has held engineering positions at Amazon Seattle and IBM Canada. His passions lie in the application of modern techniques and practices to build safe, efficient, performant, and scalable software systems.
Education: Masters of Computer Science, University of Toronto, Bachelor of Science in Computer Engineering, University of Sharjah.
Dr. Anas Al-Kassem, MD., Trauma & Bariatric Surgeon, Advisor, Medical
Dr. Anas Al-Kassem is a trauma and Bariatric surgeon who practices in Canada. Dr Al-Kassem received his MD in Damascus, Syria. He then left to Canada and completed his General Surgery training at the University of Ottawa. He did a clinical fellowship in Trauma at Foothills in Calgary. After showing leadership skills in Trauma, he was offered the position of a Trauma Team Leader at the Civic Hospital, University of Ottawa. Dr. Al-Kassem extended his surgery skills and expertise by earning a MIS/Bariatric Surgery fellowship at Baylor College of Medicine in Texas. Dr. Al-Kassem has been active in many humanitarian organizations. He is a co-founder of the Union of Medical Care and Relief organizations. He is currently the Chairman of the Union of Syrian Relief Organizations-Canada. Dr. Al-Kassem has initiated the electronic data registry system for trauma hospitals in Syria and continues to be involved in the surgery missions to support over 80 hospitals in the devastated country.
Please Read Our Disclaimer
Tactical Therapeutics Inc
Location: New York City, New York
Sector: Health .
Tactical Therapeutics, Inc is a clinical stage bio-pharma privately funded company that has developed a patented therapeutic, Carboxyamidotriazole Orotate (CTO), for treatment of glioblastomas and solid tumors.
The company has been in news world-wide since the publication of the results of CTO in Phase IB trial in forty -two glioblastoma patients. The results reported in the prestigious journal, Journal of Clinical Oncology show promising proof-of-concept and clinical effects in Glioblastomas having multiple types of genomic mutations and even in the chemo-resistant tumors. Remarkably, CTO treated glioblastoma patients demonstrated significantly longer median overall survival of twenty-eight months- the current recorded is twelve to eighteen months. Some patients remain with complete response at five years.
Four Phase I trials in one hundred patients have been completed, and two Phase II trials are planned for rGBM and nGBM. CTO has Orphan Drug Designation and the company is pursuing partnering, co-development and/or licensing strategies to ensure rapid approval of CTO to benefit GBM patients in need.
1. Strong Intellectual Property Portfolio
World-wide Intellectual Property rights lasting through 2033.
2. Safe, Effective, orally administered Drug that crosses the blood brain barrier
Competitive advantage over existing or new drugs
3. CTO has demonstrated Proof of – Concept durable partial responses in heavy treated recurrent GBM with resistant mutations, and surpassed the overall survival (05) in GBM patients with unresectable GBM – mean OS was not reached at 28 months, 2 yr OS (62%)
4. CTO has activity in multiple targets by virtue of inhibiting many types of mutations
CTO has the potential to be a block buster drug, and has competitive advantage on existing and new drugs because of properties described in #2
1. Strong Intellectual Property Protection for Drug CTO
2. Delivery of drug and safety are better than current drugs and it is unlikely that newer drugs will improve over this
3. CTO can penetrate the Blood Brian Barrier and reach the cancer cells in the brain cavity to induce its effects. The inability of most chemotherapeutic agents to cross the BBB is a major disadvantage and limitation for them to be used to treat brain tumors
4. Proof-of-Concept of efficacy demonstrated in Phase IB trial in forty-two Glioblastoma patients with pretreated and difficult to treat tumors
5. CTO when added to the standard of care treatment in recurrent GBM and in newly diagnosed GBM showed clinical effect in response in tumors with both methylated and unmethylated MGMT promotor enzyme. (This has not been seen with any other drug to date)
6. CTO has multiple targets and in GBM there are several mutations that are targets for CTO. Therefore, CTO acts comparable to a cocktail of several drugs each of which targeting one mutation only. This approach used in industry has failed
Rashida A. Karmali, JD, Ph.D., MBA, CEO and President
Dr. Karmali is Founder of TTI, Lead Scientist, Innovator, respected pioneer in cancer research. She is a registered patent and business lawyer specializing in drug discovery and development.
- After the Ph. D in Biochemistry she developed a strong Cancer Research Program and worked at Memorial Sloan-Kettering in New York. Pursuing a part-time law degree, she next became a Registered Patent lawyer.
- She worked at leading firms in New York. She started a Solo-Law practice in Technology Law & Intellectual Property in 2000 and still runs it.
- During her practice as a patent lawyer, she helped a client obtain a patent for a cancer drug (CTO), and eventually acquired its rights to develop it. Tactical Therapeutics was formed in 2005to develop this drug.
- The company’s philosophy is to develop cost effective, safe and efficacious drugs, and overcome resistance in cancers. The first target chosen to develop CTO is for glioblastoma a difficult to treat brain cancer, for which there is a critical need for drugs. The Clinical development of CTO in Glioblastoma patients has progressed with encouraging clinical results in Phase IB studies by improving the overall survival.
- Dr. Karmali is planning to start two registration trials in glioblastoma patients to get CTO approved as an Orphan Drug on the fast track to fulfill the unmet need for good drugs in GBM.
Please Read Our Disclaimer
Location: Edmonton, Alberta
Health Gauge is a personal health monitoring and management solution that provides an Artificial Intelligence (AI) & machine-learning (ML) based platform solution and a device (wrist- or card- form options) to support people in tracking, understanding, and managing their health. Health Gauge’s platform allows users to communicate with and share health data with their doctor, health/wellness practitioner, family, and friends.
Health Gauge is far more than simply a wearable; it is a solution that provides deeper analysis, and higher accuracy using artificial intelligence and machine learning. Health Gauge provides greater awareness, insights, and supports, enabling people to address developing or ongoing health problems more actively.
1. High-value AI/ML platform base for advanced health solutions R&D – Our company assets provide a world-leading platform using latest generation tools such as TensorFlow as the production base for our unique Neural-Net tools that will support leading-edge R&D and end-user clients. Our platform tools will provide for an improved way for new machine-learning and AI tools to serve people in ongoing health monitoring and management.
2.World class & highly specialized skills in AI & ML development – The University of Alberta, where all of our core team is trained, is a top-three world leader in creating highly-skilled and valuable resources in AI/ML development, engineering and microelectronics, and health sciences. Our team is in high demand for our capabilities and getting national and international notice for our work. We have 2 resources with M.Sc. degrees in advanced AI/ML skills and have augmented that with additional software, engineering, and business skills.
3.Strong connections with University of Alberta / Comp.Science, Health Sciences, and Engineering –In 2017, Google’s DeepMind organization made Edmonton, AB it’s first international investment growth location, based on the experience and profile of educators and talent here to serve Google’s growth needs. Our work taps into the same core asset base but with a core focus on the high value market opportunities in the health sector, advanced research into new AI/ML applications, and IoT development.
4.Unique and extendable IP assets with a global market opportunity – The team began to establish its IP/patent stratagem in 2015 and has recently submitted its patent to the Canadian and US patent offices, after a period of development work that extended through 2017. We are now in a position to undertake additional IP/patent work to grow and further extend our initial patent strategy.
5.Strong development partners in advanced software, IoT, manufacturing and health sciences – Over the past two years we have been meeting with a number of organizations locally and in different parts of the world – meeting with people who share our vision for the future of health monitoring and management, that serve people in ways they’ve never experienced before. We have established a number of important connections that we feel will help us scale fast and grow our business quickly.
6.High profile first client opportunities with AHS, icddr,b and Government of Canada (Military) – The Company is in negotiations with high profile clients in Canada, the United States, and Asia – who want to acquire in the overall Health Gauge product offering. The high value assets relate to the Company’s key focus and competencies in AI/ML applications, focus on consumer-health interests, and providing latest generation solutions that enhance and support the health system in the use of advanced technologies to serve end-users.
Randy Duguay, CEO, and Co-founder
Randy Duguay has been involved in new solutions development for over twenty-five years and has worked in health solutions development for over fifteen years. He is a former executive within TELUS Health Solutions (2002 – 2012) and worked with TELUS Communications for 25 year working in telecom engineering, operations, national projects, strategic & corporate strategy, product development, and commercialization. Randy was one of the first resources in TELUS Health, now Canada’s leading health technology service provider generating now over $750m in annual revenues.
In addition to working with TELUS, Randy also has worked with the University of Alberta as a Commercialization Officer (contracted) on two occasions for special projects in wireless physiological wearables, and in review of an Virtual Reality data centre joint venture.
Bruce Matichuk, CTO, and Co-founder
Bruce Matichuk, MSc. has been in the software industry for 25+ years focusing on the application of AI to real world problems. In the 90s, Bruce developed an AI based integration system that was popular with Fortune 500 companies including Liberty Mutual Insurance Company, Holiday Inn, Lockheed Martin and others.
He was one of the founders of Poynt, Canada’s first search engine company, and was a founder in Clinitrust, the first Canadian based secure email and communications platform for doctors and patients. Recently Bruce co-founded Salu Design Group Inc. to enter the personal health monitoring and analytics market. Salu is using AI/ML techniques to measure and analyze biometrics for hypertension management. AI is a passion for Bruce and he regularly speaks on its emergence and impact, and how businesses can use AI for their benefit.